Brought to you by 
Celgene to pay $2.9bn to acquire Abraxis BioScience
16 Sep 2013
Executive Summary
Publicly traded Abraxis BioScience Inc. (nanoparticle-based cancer drugs) has agreed to be acquired by Celgene Corp. for $2.9bn. For each of its company's shares held, Abraxis stockholders will receive $58 in cash and 0.2617 Celgene shares, or about $72 per share (a 17% premium).
Deal Industry
- Pharmaceuticals
-
Pharmaceuticals
-
Drug Delivery
- Site Specific
-
Drug Delivery
-
Biotechnology
- Nanotechnology, Chips, etc.
Deal Status
- Final
Deal Type
-
Acquisition
- Full Acquisition
- Includes Contract
- Includes Earnout
- Intra-Biotech Deal
- Payment Includes Cash
- Payment Includes Stock
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Celgene to pay $2.9bn to acquire Abraxis BioScience
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice